Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for Primary Prevention of Coronary Artery Disease
NCT05175274Phase 3Not yet recruiting
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Dec 2022
- Primary completion
- Mar 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of colchicine in coronary artery disease (CAD), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05175274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05175274.